TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Botanix Pharmaceuticals Limited ( (AU:BOT) ).
Botanix Pharmaceuticals Limited has announced the issuance of unquoted equity securities, specifically options exercisable at different prices and expiring in 2026 and 2028. This issuance is part of an employee incentive scheme and is not intended to be quoted on the ASX, which may impact the company’s financial strategies and employee engagement initiatives.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$0.27 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of dermatology and antimicrobial products. The company is engaged in advancing innovative therapies for skin diseases and infections, aiming to address unmet medical needs in these areas.
Average Trading Volume: 15,435,985
Technical Sentiment Signal: Sell
Current Market Cap: A$294.2M
For an in-depth examination of BOT stock, go to TipRanks’ Overview page.